secwatch.observer — SEC 8-K summary
======================================

Issuer:     FibroBiologics, Inc. (FBLG)
CIK:        0001958777
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001193125-26-041187
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroBiologics receives Nasdaq delisting notice for continued MVLS non-compliance
--------------------------------------------------------------------------------

- Nasdaq notified FibroBiologics on Feb 3, 2026 that continued failure to meet the $35M MVLS minimum adds a delisting basis.
- The Panel will consider the company's plan to regain compliance with both the bid price and MVLS rules at a hearing.
- FibroBiologics filed a proxy seeking shareholder approval for a reverse stock split (1:5 to 1:30) to address bid price deficiency.
- Trading continues pending the Panel's decision; no assurance of an extension or successful compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526041187/0001193125-26-041187-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1958777/000119312526041187/fblg-20260203.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-041187

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer